J
Joel Oger
Researcher at University of British Columbia
Publications - 168
Citations - 10523
Joel Oger is an academic researcher from University of British Columbia. The author has contributed to research in topics: Multiple sclerosis & Myasthenia gravis. The author has an hindex of 48, co-authored 166 publications receiving 9893 citations. Previous affiliations of Joel Oger include University of Mainz & Vancouver General Hospital.
Papers
More filters
Journal ArticleDOI
A full genome search in multiple sclerosis
George C. Ebers,K Kukay,Dennis E. Bulman,A D Sadovnick,George P.A. Rice,Carol M. Anderson,H. Armstrong,K Cousin,Robert B. Bell,W Hader,Donald W. Paty,S Hashimoto,Joel Oger,Pierre Duquette,Sharon Warren,T. Gray,Paul O'Connor,Avindra Nath,A. Auty,Luanne M. Metz,Gordon S. Francis,J E Paulseth,T J Murray,William Pryse-Phillips,R. F. Nelson,Matthew L. Freedman,Donald G. Brunet,Jean-Pierre Bouchard,David A. Hinds,Neil Risch +29 more
TL;DR: The results support genetic epidemiological evidence that several genes interact epistatically to determine heritable susceptibility in multiple sclerosis.
Journal ArticleDOI
MRI in the diagnosis of MS A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Donald W. Paty,Joel Oger,Lorne F. Kastrukoff,S. A. Hashimoto,John P. Hooge,Andrew Eisen,K. A. Eisen,S. J. Purves,M. D. Low,V. Brandejs,W. D. Robertson,David Kb Li +11 more
TL;DR: MRI was the best method for demonstrating dissemination in space and laboratory-supported definite MS (LSDMS) could be diagnosed in 85 patients of the total 200, and MRI predicted that diagnosis in 18/19 (95%).
Journal Article
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Gordon S. Francis,R Hughes,J King,P Mitchell,J Joubert,J McLeod,G Parker,John D. Pollard,Sindic Cjm.,T Duprez,R Medaer,J Broeckx,E Vanroose,H Carton,G Wilms,George P.A. Rice,George C. Ebers,D H Lee,Matthew L. Freedman,R. F. Nelson,H Rabinovitch,S Christie,L Avruch,Joel Oger,Donald W. Paty,D Li,J Wikstrom,Salonen Olm.,M Panelius,J.P. Eralinna,P Sonninen,P Rieckmann,D Hahn,P Flachenecker,H.-P. Hartung,Bernard M. J. Uitdehaag,F W Bertelsmann,Frederik Barkhof,O R Hommes,Jongen Pjh.,P.A. van Doorn,Tanghe Hlg.,Magnhild Sandberg-Wollheim,E M Larsson,M Lonntoft,S Sallerfors,Ludwig Kappos,C Lienert,E W Radu,M Chofflon,S Roth,V Castillo,A F Schwieger,Hughes Rac.,A M Clews,J B Bingham,D Barnes,A G Clifton,N Stoy,D Bates,A Coulthard,L D Blumhardt,S M Evans,T Jaspan,J Palace,J M Newsom-Davis,James V. Byrne,G Quaghebeur,Li Dkb.,G J Zhao,A Riddehough,B Rhodes,Grp Prismss.,Anal Ubcmsmri. +73 more
TL;DR: Clinical and MRI benefit continued for both doses up to 4 years, with evidence of dose response, and outcomes were consistently better for patients treated for 4 years than for patients in crossover groups.
Journal ArticleDOI
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray,J. Yaouanq,Emmanuelle Le Page,M. Coustans,David Laplaud,Joel Oger,Gilles Edan,Gilles Edan +7 more
TL;DR: The results indicated that the disability progression during Phase 2 was independent of that during Phase 1, demonstrating that multiple sclerosis disability progression follows a two-stage process, with a first stage probably dependant on focal inflammation and a second stage probably independent of current focal inflammation.
Journal ArticleDOI
Depression and multiple sclerosis
A D Sadovnick,R. A. Remick,J. M. Allen,E. Swartz,I. M. L. Yee,K. Eisen,R. Farquhar,S. A. Hashimoto,John P. Hooge,Lorne F. Kastrukoff,W. Morrison,J. Nelson,Joel Oger,Donald W. Paty +13 more
TL;DR: Although there appears to be a very high rate of depression among multiple sclerosis patients, the data for their first-degree relatives do not support a clear genetic basis for this depression, or at least the same genetic basis that probably operates within families when depression occurs in the absence of MS.